Custom Orforglipron CAS 2212020-52-3 - Quality Product from China Suppliers and Trusted Factory Quotes, Service

Introducing our high-quality products made in China, where we collaborate directly with trusted suppliers and our own dedicated factory to ensure premium craftsmanship and reliability. Our extensive network of suppliers enables us to provide a diverse range of products tailored to meet your needs. Each item is meticulously produced in our factory, adhering to rigorous quality standards. By choosing our products, you are not only investing in exceptional quality but also supporting local manufacturing in China. Experience the perfect blend of innovation and tradition with our offerings today!

Product Description

Orforglipron is an investigational oral medication being developed by Eli Lilly for treating type 2 diabetes and obesity. It is a non-peptide GLP-1 receptor agonist, meaning it mimics the effects of a natural hormone that regulates blood sugar and appetite. Clinical trials have shown that orforglipron can lead to significant weight loss and improved blood sugar control in people with type 2 diabetes and obesity.

Mechanism & Efficacy

Orforglipron is a novel GPR40 (FFAR1) agonist, designed to enhance insulin secretion in response to elevated glucose levels. By selectively activating GPR40 receptors in pancreatic β-cells, Orforglipron improves glucose-dependent insulin release, potentially offering benefits in type 2 diabetes management. Early clinical data suggest improvements in glycemic control, HbA1c reduction, and beta-cell function, making it a promising candidate for research and development.

Dosage & Clinical Use

In original research studies, Orforglipron has been administered as an oral tablet, with doses typically ranging from 10 mg to 50 mg per day, adjusted according to clinical trial protocols and patient response. Dosage may vary in experimental studies, and all applications should follow ethical and regulatory guidelines.
Frequently Asked Questions
What is Orforglipron used for?
Orforglipron is an investigational oral medication developed by Eli Lilly, primarily targeted for the treatment of type 2 diabetes and obesity.
How does Orforglipron work in the body?
It functions as a non-peptide GLP-1 receptor agonist and a novel GPR40 (FFAR1) agonist. It mimics natural hormones to regulate blood sugar and appetite, while also selectively activating receptors in pancreatic β-cells to enhance glucose-dependent insulin release.
What are the main benefits observed in clinical trials?
Early clinical data indicates that Orforglipron can lead to significant weight loss, improved glycemic control, HbA1c reduction, and enhanced beta-cell function.
How is Orforglipron administered?
Unlike many other GLP-1 receptor agonists that require subcutaneous injections, Orforglipron is conveniently administered as an oral tablet.
What is the typical dosage for this medication?
In research studies, doses typically range from 10 mg to 50 mg per day. The exact dosage is adjusted according to specific clinical trial protocols and individual patient responses.

Related Products